The funding marks the second cycle of CZI's Essential Open Source Software program, which awards between $50,000 and $250,000 in total costs per project.
Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.
The company is now marketing what it calls its Pharma Research Solutions, including a more flexible array of molecular analyses than its existing NeXT platform.
The study, which is being supported by Thermo Fisher Scientific, aims to identify genetic biomarkers that can predict patients likely to develop severe disease.
The HRM-based method developed by Chinese researchers could also serve as an alternative genetic test when other methods are unavailable or too expensive.
Second Genome will use its Microbiome Analytics platform to identify novel biomarkers linked to clinical responses to Gilead's investigational medicines.
High throughput and deep coverage have allowed firms like Olink and Somalogic to make inroads, especially among researchers working outside proteomics.
The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.
The technology uses photostable and bright phosphor-integrated dots for quantitative, amplification-free detection of proteins at cellular and subcellular levels.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
